Xarelto And Eylea Keep Bayer Buoyant
Despite Shadow Cast By Roundup Lawsuits
Executive Summary
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
You may also be interested in...
Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
A Rocky First Quarter For Big Pharma Stocks
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Novartis’s Beovu Launch Clouded By Safety Worries
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.